04 July 2014 | News | By BioSpectrum Bureau
Taiwan has been increasingly promoting its generic market
Singapore: Beximco pharmaceuticals, a Bangladeshi pharma giant announced that it had received Good Manufacturing Practices approval from the Taiwan Food and Drug Administration (TFDA). The approval was issued for its oral solid, inhaler and sterile eye drop facilities.
This distinguishes Beximco pharma as the first Bangladeshi firm to get accreditation by the TFDA.
The TFDA is considered to be the most stringent regulatory body in the world, and this prestigious approval promised Beximco of newer markets and revenue pools in the Asian continent including Taiwan.
Taiwan is increasingly promoting generic drugs and this has attracted the interest of many generic giants to seek approval from the TFDA. Beximco has many foreign approvals and is currently exporting to countries like Australia, Brazil and Europe.
Mr Nazmul Hassan, managing director, Beximco said that this milestone achievement was a testimony of the high quality and compliance practices followed by the firm. He added that this was a significant step in making the firm a global player in generics.